Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Aberrant AKT activation drives well-differentiated liposarcoma

Open access
Gutierrez, Alejandro, Snyder, Eric L., Marino-Enriquez, Adrian, Zhang, Yi-Xiang, Sioletic, Stefano, Kozakewich, Elena, Grebliunaite, Ruta, Ou, Wen-bin, Sicinska, Ewa, Raut, Chandrajit P., Demetri, George D., Perez-Atayde, Antonio R., Wagner, Andrew J., Fletcher, Jonathan A., Fletcher, Christopher D. M., Look, A. Thomas · 2011 · Proceedings of the National Academy of Sciences

Abstract

Well-differentiated liposarcoma (WDLPS), one of the most common human sarcomas, is poorly responsive to radiation and chemotherapy, and the lack of animal models suitable for experimental analysis has seriously impeded functional investigation of its pathobiology and development of effective targeted therapies. Here, we show that zebrafish expressing constitutively active Akt2 in mesenchymal progenitors develop WDLPS that closely resembles the human disease. Tumor incidence rates were 8% in p53 wild-type zebrafish, 6% in p53 heterozygotes, and 29% in p53 -homozygous mutant zebrafish ( P = 0.013), indicating that aberrant Akt activation collaborates with p53 mutation in WDLPS pathogenesis. Analysis of primary clinical specimens of WDLPS, and of the closely related dedifferentiated liposarcoma (DDLPS) subtype, revealed immunohistochemical evidence of AKT activation in 27% of cases. Western blot analysis of a panel of cell lines derived from patients with WDLPS or DDLPS revealed robust AKT phosphorylation in all cell lines examined, even when these cells were cultured in serum-free media. Moreover, BEZ235, a small molecule inhibitor of PI3K and mammalian target of rapamycin that effectively inhibits AKT activation in these cells, impaired viability at nanomolar concentrations. Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.1106127108

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 2

  1. AP Dei Tos, F Pedeutour, Atypical lipomatous tumor/well differentiated liposarcoma; Dedifferentiated liposarcoma. Pathology and Genetics of Tumors of Soft Tissue and Bone: World Health Organization Classification of Tumors., ed CDM Fletcher (IARC press, Lyon), pp. 35–39 (2002).
  2. 10.1002/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O · doi:10.1002/(sici)1096-9896(199701)181:1<14::aid-path730>3.0.co;2-o

Cited by

See all 58

Metadata

Authors
Gutierrez, A., Snyder, E. L., Marino-Enriquez, A., Zhang, Y.-X., Sioletic, S., Kozakewich, E., Grebliunaite, R., Ou, W.-B., Sicinska, E., Raut, C. P., Demetri, G. D., Perez-Atayde, A. R., Wagner, A. J., Fletcher, J. A., Fletcher, C. D. M., & Look, A. T.
Affiliations
  • Department of Pediatric Oncology,
  • Harvard University (US)
  • Department of Pathology and
  • The Ludwig Center at Dana-Farber/Harvard Cancer Center, and
  • Department of Medical Oncology and Center for Molecular Oncologic Pathology,
  • Brigham and Women's Hospital (US)
  • Department of Pathology, Children's Hospital, Boston, MA 02115;
  • Dana-Farber Cancer Institute (US)
Venue
Proceedings of the National Academy of Sciences
Published
2011-09-19
Volume
108
Issue
39
Pages
16386-16391
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1982933649
Cited by
58
References
27
Citations by year
2026: 5 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 5 · 2012: 2
FWCI
4.08
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • National Cancer Institute (K08CA154784, K08CA133103)
  • National Center for Research Resources (UL1RR025758)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
well-differentiated liposarcoma, dedifferentiated liposarcoma, Akt activation, AKT2, TP53 mutation, zebrafish tumor model, mesenchymal progenitor cells, BEZ235, PI3K/mTOR inhibition, chemoresistance, therapeutic target, sarcoma pathogenesis
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Animals, Cell Cycle, Cell Differentiation, Enzyme Activation, Humans, Immunohistochemistry, Liposarcoma, Mutation, Zebrafish, Blotting, Western, Genes, p53, Apoptosis, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aberrant AKT activation drives well-differentiated liposarcoma. https://app.cochat.ai/papers/10.1073/pnas.1106127108
The paper
Gutierrez, A., Snyder, E. L., Marino-Enriquez, A., Zhang, Y.-X., Sioletic, S., Kozakewich, E., Grebliunaite, R., Ou, W.-B., Sicinska, E., Raut, C. P., Demetri, G. D., Perez-Atayde, A. R., Wagner, A. J., Fletcher, J. A., Fletcher, C. D. M., & Look, A. T. (2011). Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1106127108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.